Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections on July 17, 2026 Alvotech Biosimilars Bloomington Indiana Cautionary Warning Letter [Publication Type] Ozempic Plainsboro New Jersey Qualitative form Reykjavik plant scrutiny United States Food and Drug Administration +
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement on June 18, 2026 Alvotech biosimilar medicines Concurrent development aspects Options private placement public entity research underwriters working capital +